Which psychedelics are legal in the US in 2026 — ketamine, psilocybin, ayahuasca, and the FDA pipeline.
Ketamine is the only psychedelic that is legal nationwide across the United States, classified as Schedule III and approved by the Food and Drug Administration (FDA) as Spravato. Psilocybin is legal only in licensed, supervised settings in Oregon and Colorado. Personal possession of psilocybin, DMT, and non-peyote mescaline is decriminalized statewide in Colorado. Psilocybin enforcement specifically is also deprioritized in over 20 cities. Religious exemptions protect ceremonial ayahuasca for four DEA-recognized churches. Peyote is protected only for enrolled members of the Native American Church. MDMA, LSD, ibogaine, and 5-MeO-DMT remain illegal nationwide outside clinical trials.
The list below sorts this into five tiers, from federally legal to not legal anywhere outside a clinical trial. Decriminalization is its own tier because it does not make a substance legal. The table after the list maps US legal status by substance as of May 2026.
Because "legal" can mean federal law, state law, or just a city's enforcement policy, the fastest way to check one specific state is the legal status by state tool, which tracks psilocybin, DMT, MDMA, ketamine, and ibogaine law state by state. One more nuance worth flagging: research chemicals sold online, like 4-AcO-DMT, aren't explicitly scheduled by name in most states, but are still prosecuted as Schedule I under the Federal Analogue Act when intended for human consumption — "not explicitly listed" is not the same as legal.
| Substance | US Federal Status | Where Accessible (US) | Easiest Legal Access |
|---|---|---|---|
| Ketamine | Schedule III | All 50 states (clinics + telehealth) | Oral ketamine via telehealth platform (prescription, mailed lozenges, remote sessions) |
| Psilocybin | Schedule I | Oregon (licensed centers), Colorado (healing centers) | Oregon service center — no prescription needed, 21+ |
| Ayahuasca (DMT) | Schedule I | 4 DEA-exempted religious churches (US); widely abroad | UDV or Santo Daime ceremony (if you qualify); or Peru/Netherlands retreats |
| MDMA | Schedule I | FDA clinical trials only | Enroll in a MAPS-successor or university MDMA trial (ClinicalTrials.gov) |
| LSD | Schedule I | Definium Therapeutics DT120 (formerly MindMed MM120) Phase 3 trials only | Voyage (Aug 2026) and Panorama (Sep 2026) both reported positive topline results for GAD |
| Ibogaine | Schedule I | FDA-IND trials (Texas IMPACT) only | Licensed clinics in Mexico (not subject to US law) |
| 5-MeO-DMT | Schedule I | GH Research GH001 trials (select sites) | Retreat in Costa Rica or Mexico (not subject to US law) |
| Mescaline (peyote) | Schedule I* | Native American Church members (federal statutory exemption) | N/A — NAC exemption is for enrolled tribal members, not the general public |
| Mescaline (non-peyote) | Schedule I | Colorado (decriminalized personal possession, Prop 122) | Colorado only — no licensed program for mescaline (non-peyote) yet |
Ketamine is the outlier: it is Schedule III (not Schedule I), and it has an FDA-approved product. Spravato (esketamine nasal spray) was approved in 2019 for treatment-resistant depression (TRD) and in 2020 for major depressive disorder with acute suicidal ideation. Spravato requires in-office administration and a 2-hour observation period at a certified healthcare setting.
Off-label IV/IM/sublingual ketamine is also widely prescribed through ketamine clinics and, increasingly, telehealth platforms that mail oral ketamine lozenges with remote monitoring sessions. This is currently the most cost-effective and accessible psychedelic-adjacent therapy in the US.
Cost range: Spravato with insurance may cost $10–$100/session (but requires in-office administration). IV ketamine at clinics: $400–$800/infusion. Telehealth ketamine (oral): $150–$300/month including lozenges and sessions. Full ketamine guide →
Psilocybin is the most researched classical psychedelic and the most likely next substance to achieve broader legal access in the US. Two legal pathways exist:
Product cannot legally leave either state afterward. Sessions must be completed on-site, and transporting psilocybin home remains illegal under both state and federal law regardless of where the session took place.
In all other US states, psilocybin remains Schedule I. The FDA has granted Breakthrough Therapy designation to both COMPASS Pathways and Usona Institute for psilocybin — Phase 3 trials are ongoing. Full psilocybin guide →
A separate question trips up first-time buyers: psilocybin mushroom spores are not the same substance. Spores contain no psilocybin or psilocin, so they are legal to buy, sell, and possess in most US states — the material only becomes Schedule I once it germinates into mycelium. Are psilocybin spores legal? →
DMT — the active compound in ayahuasca — is Schedule I. The Religious Freedom Restoration Act (RFRA), as interpreted by the Supreme Court in Gonzales v. O Centro Espírita Beneficente União do Vegetal (2006), permits four specific US religious organizations to use ayahuasca in genuine religious ceremonies:
Outside these four organizations, ceremonial ayahuasca is illegal in the US. Most US residents legally access ayahuasca through retreats in Peru, Costa Rica, the Netherlands, or Jamaica. Full ayahuasca guide → Colorado is a separate case: Prop 122 decriminalizes personal possession of DMT itself statewide for adults 21+, separate from the narrower religious exemption for the four DEA-recognized churches. Full DMT legal-status guide →
MDMA-assisted therapy has the strongest published evidence for PTSD of any psychedelic, but the FDA rejected Lykos Therapeutics' NDA in August 2024, citing issues with the trial design, blinding, and functional unblinding. A new Phase 3 trial is required before MDMA can be prescribed legally in the US.
Australia is currently the only country where psychiatrists can legally prescribe MDMA for PTSD via TGA's Authorised Prescriber scheme. Access is limited and expensive (~$25,000 AUD per course of treatment).
In the US, legal access is possible only through FDA-approved clinical trials. Search ClinicalTrials.gov for "MDMA PTSD" to find recruiting studies. Full MDMA guide →
The most significant near-term developments as of 2026 (the psychedelic legalization tracker follows bills as they move):
The Drug Enforcement Administration (DEA) has proposed placing five synthetic tryptamines into Schedule I of the Controlled Substances Act. On September 23, 2026, the DEA published a Notice of Proposed Rulemaking in the Federal Register (Docket No. DEA-2026-19400) covering 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT). The public comment period on this proposal runs through October 23, 2026.
The DEA first proposed scheduling these five substances in January 2022 and announced a hearing in July 2022. The DEA withdrew both notices to obtain an updated evaluation from the Department of Health and Human Services (HHS), which the DEA requested in November 2023. Citing law enforcement encounters, poison-control exposure data, and no accepted medical use, the revived proposal covers substances that lack state-legal access programs like those for psilocybin in Oregon and Colorado.
The proposal creates direct tension with Reunion Neuroscience, whose investigational postpartum depression drug luvesilocin converts into 4-OH-DiPT (the same prodrug pattern as 4-AcO-DMT converting to psilocin). The Food and Drug Administration (FDA) granted luvesilocin Breakthrough Therapy designation on February 23, 2026, supported by Phase 2 RECONNECT trial reductions in Montgomery-Asberg Depression Rating Scale (MADRS) scores by Day 7. Schedule I placement would not block clinical trials conducted under an FDA Investigational New Drug (IND) application, but it would add DEA research registration requirements.
Yes — for psilocybin in Oregon and Colorado. Licensed service centers and healing centers offer structured experiences with trained facilitators. These are not "retreats" in the informal sense; they are licensed facilities operating under state regulation with specific protocols, preparation requirements, and post-session integration support.
For other psychedelics, retreats operating legally must be outside the United States. Common legal retreat destinations:
In most US states: no. Microdosing psilocybin mushrooms or LSD involves possession of a Schedule I substance, regardless of the quantity or intended use. The size of the dose does not change the legal classification.
In Colorado, personal possession of psilocybin in any quantity for personal use is decriminalized under Prop 122. In Denver specifically, a 2019 ordinance similarly deprioritizes enforcement. In 30+ other US cities with deprioritization resolutions, local police treat enforcement as lowest priority — but state and federal law still apply.
Amanita muscaria products (containing muscimol, not psilocybin) are not federally scheduled and are legally available in most US states. They are chemically and experientially distinct from classic psilocybin mushrooms.
Psychedelic and "legal high" legality also varies enormously outside the US — by country and often by city. Rather than guess at an unresearched jurisdiction, use the site's own verified coverage: the LSD international-status table, the DMT guide's country-by-country breakdown, the ibogaine guide's international section, and the retreat finder for legal retreat destinations (Netherlands, Portugal, Jamaica, Mexico, Costa Rica). For anywhere not covered there, check that country's own drug-scheduling authority directly before relying on a search result.
Psilocybin, LSD, DMT, mescaline, ibogaine, and MDMA are Schedule I under the federal Controlled Substances Act, signed by President Nixon on October 27, 1970. Schedule I is the most restrictive category: it requires a finding of high abuse potential, no currently accepted medical use in the US, and a lack of accepted safety for use under medical supervision. That classification — not a state-by-state patchwork — is why a doctor cannot prescribe any of these substances even in states that have decriminalized possession. Full breakdown of the Controlled Substances Act and the rescheduling process →
Ketamine is the only psychedelic-adjacent substance that is both federally legal and widely accessible — it is Schedule III and has an FDA-approved product (Spravato). Psilocybin is legal in licensed programs in Oregon and Colorado. Ayahuasca (DMT) is legal only for members of four DEA-recognized religious churches. MDMA, LSD, ibogaine, and 5-MeO-DMT are Schedule I with no approved US use; access is limited to clinical trials.
Yes. Ketamine is Schedule III (not Schedule I) and has FDA-approved uses: Spravato (esketamine) for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Off-label IV/IM/sublingual ketamine is also widely prescribed by clinics nationwide and via telehealth. Whether ketamine is a 'psychedelic' is debated — it is classified as a dissociative, not a classical 5-HT2A agonist — but it is the most accessible legal psychedelic-adjacent substance in the US.
Yes, but only through the licensed programs in Oregon and Colorado. Both require on-site facilitation, and no psilocybin product may be taken home. Oregon's Measure 109 service centers have operated since 2023, and Colorado's Prop 122 healing centers are licensing. New Mexico has enacted a medical psilocybin program that is not yet operating. Outside these programs, psilocybin remains a Schedule I controlled substance in every state.
Yes, for psilocybin only. Oregon and Colorado both have licensed service center / healing center programs where adults 21+ can receive facilitated psilocybin sessions legally. For other psychedelics (ayahuasca, ibogaine, 5-MeO-DMT), legal retreats operate outside the US — in Jamaica, Peru, Netherlands, Mexico, and Costa Rica.
In most US states, no. Microdosing psilocybin or LSD involves possession of a Schedule I substance regardless of the dose. Colorado decriminalized personal psilocybin possession under Prop 122. About 30 US cities have deprioritization resolutions, but these do not make microdosing legal — state and federal law still apply.
Several concrete pathways are already in motion, though none guarantee a specific outcome or timeline. MDMA and LSD both have active Phase 3 programs — MDMA following the FDA's August 2024 Complete Response Letter and requirement for an additional trial, and MindMed's MM120 (LSD, now Definium's DT120) Voyage and Panorama Phase 3 trials, both of which reported positive topline results by September 2026. The April 2026 executive order 'Accelerating Medical Treatments for Serious Mental Illness' directs the FDA to issue National Priority Vouchers that shorten review timelines for Breakthrough Therapy-designated psychedelics and creates a Right to Try pathway for investigational use — it accelerates the regulatory process but does not itself reschedule or legalize any substance. At the state level, Colorado's Natural Medicine Health Act includes a mechanism for its Advisory Board to expand licensed healing centers to additional natural medicines (such as DMT) over time. Any of these could shift the legal picture in the coming years, but as of 2026 none has resulted in broader legalization beyond what's described on this page.
It depends on the substance. Ketamine, MDMA, LSD, DMT, and ibogaine have the same federal status in every state — Schedule III for ketamine, Schedule I for the rest — so which state you're in does not change federal legal access. Psilocybin is the exception: Oregon and Colorado have licensed access programs, and many other states and cities vary in how they enforce Schedule I possession even though the underlying law doesn't change. Our legal-status-by-state tool has a dedicated page for psilocybin law in all 50 states, and our interactive psychedelic legal map shows city-level decriminalization resolutions on top of state law.
No major health insurer, Medicare, or Medicaid covers licensed psilocybin services in Oregon or Colorado. These state-licensed programs fall outside standard insurance medical-necessity frameworks because the Food and Drug Administration (FDA) has not approved psilocybin as a medical treatment. Participants pay all session costs out of pocket. Total expenses commonly run from several hundred to a few thousand dollars depending on the facilitator and format.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.